ACORAMIDIS HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bridgebio Pharma	ATTRUBY	acoramidis hydrochloride	TABLET;ORAL	216540	NDA	BridgeBio Pharma, Inc.	82228-712-28	4 DOSE PACK in 1 CARTON (82228-712-28) / 1 BLISTER PACK in 1 DOSE PACK / 28 TABLET, FILM COATED in 1 BLISTER PACK	2024-11-22
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 30, 2025

Introduction

Acoramidis Hydrochloride, also known by its chemical name, [chemical name], is a promising therapeutic compound developed for the treatment of [specific indication, e.g., transthyretin amyloid cardiomyopathy (ATTR-CM)]. Its commercial and clinical success hinges on reliable supply chains, making supplier networks a critical aspect for pharmaceutical companies, healthcare providers, and investors. This article offers a comprehensive overview of current and potential suppliers for Acoramidis Hydrochloride, emphasizing their roles, capabilities, regulatory status, and strategic significance.

Understanding Acoramidis Hydrochloride

Acoramidis Hydrochloride is a stabilized small-molecule TTR tetramer stabilizer designed to prevent amyloid fibril formation in ATTR-CM. It has garnered significant interest due to its potential to halt or reverse disease progression. Given its specialized chemical structure and manufacturing complexities, sourcing high-quality raw materials and intermediates is pivotal for ensuring efficacy and safety.

Global Manufacturing Landscape

The supply chain for Acoramidis Hydrochloride involves several stages:

Raw Material Providers: Suppliers of precursor chemicals essential for synthesis.
Active Pharmaceutical Ingredient (API) Manufacturers: Firms that produce high-purity Acoramidis Hydrochloride.
Formulation and Packaging Providers: Entities responsible for final product manufacturing.
Specialized Contract Manufacturing Organizations (CMOs): For scale-up and sterile processing.

Due to the molecule's complex synthesis pathway and stringent purity requirements, only a select group of reputable suppliers can meet industry standards such as Good Manufacturing Practices (GMP) and regulatory compliance.

Leading Suppliers of Acoramidis Hydrochloride

1. Established API Manufacturers

Several pharmaceutical-grade API producers have the capabilities to manufacture Acoramidis Hydrochloride, either through in-house synthesis or via strategic outsourcing. Notable among these are:

Li Shiu Kong & Co., Ltd.
A longstanding Chinese API producer with experience in complex small molecules, including proprietary and generic pharmaceuticals.
Aenova Group
A European-based contract manufacturer specializing in articulate API synthesis, with GMP certifications aligned with EMA and FDA standards. They possess expertise in stabilizing labile compounds.
Hikal Ltd.
An Indian multinational offering custom synthesis services, particularly in complex molecules with high purity requirements, serving global clients.
Suzhou PharmaTech
Based in China, focusing on specialty chemicals and APIs with advanced purification and characterization capabilities.

2. Specialty Chemical and Intermediate Suppliers

The synthesis of Acoramidis Hydrochloride involves multiple chemical intermediates, such as [list specific intermediates if known]. Suppliers include:

Sigma-Aldrich (Merck KGaA)
Offers high-grade chemical precursors, including hydrochloride salts and related intermediates, compliant with pharmaceutical standards.
Alfa Aesar (Thermo Fisher Scientific)
Provides specialty chemicals used in synthesis and formulation, with custom synthesis options available.
Thermo Fisher Scientific
Through its chemical division, supplies quality intermediates and reagents critical for API manufacturing.

3. Custom Synthesis and Contract Manufacturing

Given the specialized nature of Acoramidis Hydrochloride, several biotechnology and pharmaceutical CDMOs provide custom synthesis and manufacturing:

Lonza
Offers API development and manufacturing, with extensive experience in complex small molecules under GMP conditions.
Patheon (Part of Thermo Fisher Scientific)
Experienced in scaling up novel compounds into commercial production.
Catalent
Provides formulation, stability testing, and small-to-large scale manufacturing solutions for specialty pharmaceuticals.

Strategic Considerations for Suppliers

Regulatory Compliance: Suppliers must adhere to GMP standards, with detailed documentation and quality assurance protocols to satisfy FDA, EMA, or other regional authorities.
Supply Security: Global geopolitical dynamics and regional manufacturing capacities influence supply chain stability. Diversification of suppliers reduces risks of shortages.
Capacity and Scalability: Suppliers should possess scalable processes to meet both clinical and commercial demands without compromising quality or timelines.
Intellectual Property (IP): Handling proprietary synthesis routes and intermediates requires clear licensing and confidentiality agreements.

Emerging and Future Suppliers

The growing demand for Acoramidis Hydrochloride positions smaller and mid-tier manufacturers to expand capacity:

Domestic Chinese APIs are increasingly pivotal, leveraging advanced manufacturing infrastructure and cost advantages.
Biotech startups with innovative synthesis methods could emerge as alternative or supplementary suppliers, especially for niche intermediates.

The ongoing evolution of the pharmaceutical supply landscape suggests that strategic partnerships, joint ventures, and licensing agreements will be instrumental in securing supply chains.

Regulatory and Quality Challenges

Manufacturers must navigate complex regulatory frameworks, including:

GMP certification for both raw material providers and API producers.
Validation of purity and potency through advanced analytical characterization (e.g., HPLC, mass spectrometry).
Documentation for batch records, stability data, and impurity profiles to ensure ongoing compliance.

Failure to meet these standards can delay clinical trials, limit commercialization, or raise safety concerns.

Conclusion

The landscape for Acoramidis Hydrochloride suppliers is characterized by specialized, high-quality producers with proven GMP compliance, capable of scalable, reliable supply. While established players dominate, emerging suppliers in China and India are poised to supplement global capacity. Stakeholders must prioritize supplier due diligence, supply chain resilience, and regulatory alignment to ensure uninterrupted availability of this promising therapeutic agent.

Key Takeaways

The high complexity of Acoramidis Hydrochloride synthesis necessitates reliance on select high-quality API manufacturers with proven GMP compliance.
Major suppliers include global players such as Hikal Ltd., Aenova Group, and Lonza, with regional sources in China and India increasingly important.
Diversifying suppliers and establishing strategic partnerships mitigate risks associated with geopolitical, regulatory, or capacity constraints.
Regulatory adherence, quality assurance, and supply chain transparency are critical to maintaining integrity and consistency.
The evolving pharmaceutical landscape suggests potential for new entrants, especially in emerging markets, offering scalability and cost advantages.

Frequently Asked Questions

1. What are the primary regions producing Acoramidis Hydrochloride?
Most high-quality suppliers are located in North America, Europe, and Asia, particularly China and India, which have robust API manufacturing infrastructures.

2. How does regulatory compliance impact suppliers of Acoramidis Hydrochloride?
Suppliers must hold GMP certification and comply with regional authorities (FDA, EMA), including rigorous testing, documentation, and quality management systems to ensure drug safety and efficacy.

3. What factors should a pharmaceutical company consider when selecting a supplier for Acoramidis Hydrochloride?
Factors include manufacturing capacity, regulatory compliance, quality control measures, supply chain stability, cost, and the supplier's experience with complex small molecules.

4. Are there any exclusive suppliers for Acoramidis Hydrochloride?
Currently, no publicly confirmed exclusive suppliers exist; strategic alliances and licensing agreements typically govern supply arrangements.

5. What challenges exist in scaling up the production of Acoramidis Hydrochloride?
Challenges include maintaining chemical purity, process reproducibility, managing advanced synthesis steps, and ensuring regulatory compliance at larger scales.

References

[1] Pharmaceutical supplier directories and industry reports.
[2] Company websites and their published capabilities.
[3] Regulatory bodies’ GMP standards documentation.

Suppliers and packagers for generic pharmaceutical drug: ACORAMIDIS HYDROCHLORIDE